JPMorgan Dials Back Saia Expectations After 'Shocking' Q1, Weak May Tonnage Saia Inc's daily tonnage turned negative in May, following shocking Q1 results. JPMorgan analyst reduced price target but maintained Overweight rating.
These 3 Dividend Stocks Pay You to Stay Calm in Summer This summer could be more volatile than usual, here are three high-quality dividend stocks that are solid choices for the summer and beyond
Nucor Tops JPMorgan's Metals List, Eyes 67% Surge Thanks To Tariffs Nucor is best positioned to ride out the latest tariff wave, thanks to its product diversification, a JPMorgan analyst says.
Miniso Reportedly In Talks To List Its Toy Business, Hires Bankers Miniso's plan follows the incredible rise of Chinese toymaker Pop Mart International, the company behind blind‑box figurines like Labubu, Molly, Dimoo, and Pucky.
3 Oversold Stocks Flashing Bullish Reversal Signals Here are three stocks that each have oversold RSIs. However, improving signals and catalysts could suggest we're looking at some great entry points.
JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory Acadia wins Nuplazid patent case, extending protection to 2038, as JP Morgan boosts price target ahead of key appeal on the ‘740 COM patent.
JPMorgan Trims Braze EPS Outlook As Investors React To Acquisition Growing Pains JPMorgan analyst lowered price forecast for Braze from $45 to $47, while retaining Overweight rating. Q1 earnings beat estimates, but margins reset.
Chewy's Loyalty Engine, $1B Pharmacy Business Have JPMorgan Staying Bullish Before Q1 JP Morgan's Anmuth sees Q1 sales upside and stronger FY25 margins for Chewy, driven by Autoship, high-margin segments, and cost efficiency.
Oshkosh Investor Day Shows Path To 2028 Growth, Says JPMorgan Tami Zakaria of JP Morgan raised Oshkosh (OSK) price forecast to $106 and kept a Neutral rating. OSK expects revenue of $13-$14 billion, EPS $18-$22, and EBIT margin of 12-14%. Analyst raised estimates and anticipates moderate downturn in Access Equipment sales in 2025.
Omada Health Stock Shoots Up 42% In Nasdaq Debut, Breaches $26 Mark For the quarter ended March 2025, the firm’s revenue shot up 57% year-over-year to $55 million.
5 Earnings Season Winners With More Upside on the Way Earnings season is over, but that doesn't mean the big winners are ready to fade. Read on to learn which five earnings season winners will keep climbing in Q2.
Omada Health Prices $150M IPO In-Line With Estimated Range Omada Health (OMDA) priced its IPO at $19 per share, midpoint of the previously estimated price range of $18.00 and $20.00 per share
